Abiopharma

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Journey Medical to Join Russell2000® and Russell 3000® Indexes

Baxter - Baxter Publishes Annual Corporate Responsibility Report, Demonstrating Ongoing Action to Make a Meaningful Difference Around the World

SINTX Technologies Acquires SiNAPTIC Surgical Assets and IP to Expand into $1.3B Foot and Ankle Fusion Market

PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

Omeros Announces Webcast Details for Annual Meeting of Shareholders

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

Baxter Publishes Annual Corporate Responsibility Report, Demonstrating Ongoing Action to Make a Meaningful Difference Around the World

Xenon Announces Appointment of Darren Cline as Chief Commercial Officer

CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer

Nuvation Bio Inc. - Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib(IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities

New Form 8-K - PAVmed Inc. Filed: 2025-06-24 AccNo: 0001641172-25-016227 Size: 210 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits